r-bPiDI, an α6β2* Nicotinic Receptor Antagonist, Decreases Nicotine-Evoked Dopamine Release and Nicotine Reinforcement

详细信息    查看全文

• 作者：Joshua S. Beckmann ; Andrew C. Meyer ; M. Pivavarchyk…
• 关键词：Nicotine ; Abuse ; Dopamine ; Reinforcement
• 刊名：Neurochemical Research
• 出版年：2015
• 出版时间：October 2015
• 年：2015
• 卷：40
• 期：10
• 页码：2121-2130
• 全文大小：588 KB
• 参考文献：1.Shiffman S, Hickcox M, Paty JA, Gnys M, Kassel JD, Richards TJ (1996) Progression from a smoking lapse to relapse: prediction from abstinence violation effects, nicotine dependence, and lapse characteristics. J Consult Clin Psychol 64:993-002CrossRef PubMed
  2.Fiore MC (2008) Treating tobacco use and dependence: 2008 update: clinical practice guideline. DIANE Publishing, Pennsylvania
  3.Harmey D, Griffin PR, Kenny PJ (2012) Development of novel pharmacotherapeutics for tobacco dependence: progress and future directions. Nicotine Tob Res 14:1300-318PubMedCentral CrossRef PubMed
  4.Hajek P, Stead LF, West R, Jarvis M, Hartmann-Boyce, J, Lancaster T (2013) Relapse prevention interventions for smoking cessation. Cochrane Database Syst Rev. Art. No. CD003999. doi:10.-002/-465188458
  5.Corrigall WA (1991) Understanding brain mechanisms in nicotine reinforcement. Br J Addict 86:507-10CrossRef PubMed
  6.Picciotto MR, Corrigall WA (2002) Neuronal systems underlying behaviors related to nicotine addiction: neural circuits and molecular genetics. J Neurosci 22:3338-341PubMed
  7.Wise RA, Rompre PP (1989) Brain dopamine and reward. Annu Rev Psychol 40:191-25CrossRef PubMed
  8.Salminen O, Murphy KL, McIntosh JM, Drago J, Marks MJ, Collins AC, Grady SR (2004) Subunit composition and pharmacology of two classes of striatal presynaptic nicotinic acetylcholine receptors mediating dopamine release in mice. Mol Pharmacol 65:1526-535CrossRef PubMed
  9.Gotti C, Moretti M, Clementi F, Riganti L, McIntosh JM, Collins AC, Marks MJ, Whiteaker P (2005) Expression of nigrostriatal alpha 6-containing nicotinic acetylcholine receptors is selectively reduced, but not eliminated, by beta 3 subunit gene deletion. Mol Pharmacol 67:2007-015CrossRef PubMed
  10.Visanji NP, O’Neill MJ, Duty S (2006) Nicotine, but neither the alpha4beta2 ligand RJR2403 nor an alpha7 nAChR subtype selective agonist, protects against a partial 6-hydroxydopamine lesion of the rat median forebrain bundle. Neuropharmacology 51:506-16CrossRef PubMed
  11.Yang KC, Jin GZ, Wu J (2009) Mysterious alpha6-containing nAChRs: function, pharmacology, and pathophysiology. Acta Pharmacol Sin 30:740-51PubMedCentral CrossRef PubMed
  12.Pons S, Fattore L, Cossu G, Tolu S, Porcu E, McIntosh JM, Changeux JP, Maskos U, Fratta W (2008) Crucial role of alpha4 and alpha6 nicotinic acetylcholine receptor subunits from ventral tegmental area in systemic nicotine self-administration. J Neurosci 28:12318-2327PubMedCentral CrossRef PubMed
  13.Faure P, Tolu S, Valverde S, Naude J (2014) Role of nicotinic acetylcholine receptors in regulating dopamine neuronal activity. Neuroscience 282:86-00CrossRef
  14.Sanjakdar SS, Maldoon PP, Marks MJ, Brunzell DH, Maskos U, McIntosh JM, Bowers MS, Damaj MI (2015) Differential roles of α6β2* and α4β2* neuronal nicotinic receptors in nicotine- and cocaine-conditioned reward in mice. Neuropsychopharmacology 40:350-60CrossRef PubMed
  15.Drenan RM, Grady SR, Whiteaker P, McClure-Begley T, McKinney S, Miwa JM, Bupp S, Heintz N, McIntosh JM, Bencherif M, Marks MJ, Lester HA (2008) In vivo activation of midbrain dopamine neurons via sensitized, high-affinity alpha 6 nicotinic acetylcholine receptors. Neuron 60:123-36PubMedCentral CrossRef PubMed
  16.Wang Y, Lee JW, Oh G, Grady SR, McIntosh JM, Brunzell DH, Cannon JR, Drenan RM (2014) Enhanced synthesis and release of dopamine in transgenic mice with gain-of-function α6* nAChRs. J Neurochem 129:315-27PubMedCentral CrossRef PubMed
  17.Moretti M, Mugnaini M, Tessari M, Zoli M, Gaimarri A, Manfredi I, Pistillo F, Clementi F, Gotti C (2010) A comparative study of the effects of the intravenous self-administration or subcutaneous minipump infusion of nicotine on the expression of brain neuronal nicotinic receptor subtypes. Mol Pharmacol 78:287-96CrossRef PubMed
  18.Marks MJ, Grady SR, Salminen O, Paley MA, Wageman CR, McIntosh JM, Whiteaker P (2014) α6β2*-subtype nicotinic acetylcholine receptors are more sensitive than α4β2*-subtype receptors to regulation by chronic nicotine administration. J Neurochem 130:185-98PubMedCentral CrossRef PubMed
  19.Perez XA, McIntosh JM, Quik M (2013) Long-term nicotine treatment downregulates α6β* nicotinic receptor expression and function in nucleus accumbens. J Neurochem 127:762-71CrossRef PubMed
  20.Kulak JM, Nguyen TA, Olivera BM, McIntosh JM (1997) Alpha-conotoxin MII blocks nicotine-stimulated dopamine release in rat striatal synaptosomes. J Neurosci 17:5263-270PubMed
  21.Exley R, Clements MA, Hartung H, McIntosh JM, Cragg SJ (2008) Alpha6-containing nicotinic acetylcholine receptors dominate the nicotine control of dopamine neurotransmission in nucleus accumbens. Neuropsychopharmacology 33:2158-166CrossRef PubMed
  22.Gotti C, Guiducci S, Tedesco V, Corbioli S, Zanetti L, Moretti M, Zanardi A, Rimondini R, Mugnaini M, Clementi F, Chiamulera C, Zoli M (2010) Nicotinic acetylcholine receptors in the
• 作者单位：Joshua S. Beckmann (1)
  Andrew C. Meyer (1)
  M. Pivavarchyk (2)
  David B. Horton (2)
  Guangrong Zheng (3)
  Andrew M. Smith (2)
  Thomas E. Wooters (1)
  J. Michael McIntosh (4)
  Peter A. Crooks (3)
  Michael T. Bardo (1)
  Linda P. Dwoskin (2)
  
  1. Department of Psychology, University of Kentucky, Lexington, KY, USA
  2. Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, 789 S. Limestone St., Lexington, KY, 40536-0596, USA
  3. Department of Pharmaceutical Sciences, University of Arkansas for Medical Sciences, Little Rock, AR, USA
  4. George E. Wahlen Veterans Affairs Medical Center and Departments of Psychiatry and Biology, University of Utah, Salt Lake City, UT, USA
  
• 刊物类别：Biomedical and Life Sciences
• 刊物主题：Biomedicine
  Neurosciences
  Biochemistry
  Neurology
  
• 出版者：Springer Netherlands
• ISSN：1573-6903

文摘

α6β2* nicotinic acetylcholine receptors (nAChRs) expressed by dopaminergic neurons mediate nicotine-evoked dopamine (DA) release and nicotine reinforcement. α6β2* antagonists inhibit these effects of nicotine, such that α6β2* receptors serve as therapeutic targets for nicotine addiction. The present research assessed the neuropharmacology of 1,10-bis(3-methyl-5,6-dihydropyridin-1(2H)-yl)decane (r-bPiDI), a novel small-molecule, tertiary amino analog of its parent compound, N,N-decane-1,10-diyl-bis-3-picolinium diiodide (bPiDI). bPiDI was previously shown to inhibit both nicotine-evoked DA release and the reinforcing effects of nicotine. In the current study, r-bPiDI inhibition of [3H]nicotine and [3H]methyllycaconitine binding sites was evaluated to assess interaction with the recognition binding sites on α4β2* and α7* nAChRs, respectively. Further, r-bPiDI inhibition of nicotine-evoked DA release in vitro in the absence and presence of α-conotoxin MII and following chronic in vivo nicotine administration were determined. The ability of r-bPiDI to decrease nicotine self-administration and food-maintained responding was also assessed. Results show that r-bPiDI did not inhibit [3H]nicotine or [3H]methyllycaconitine binding, but potently (IC₅₀ = 37.5 nM) inhibited nicotine-evoked DA release from superfused striatal slices obtained from either drug na?ve rats or from those repeatedly treated with nicotine. r-bPiDI inhibition of nicotine-evoked DA release was not different in the absence or presence of α-conotoxin MII, indicating that r-bPiDI acts as a potent, selective α6β2* nAChR antagonist. Acute systemic administration of r-bPiDI specifically decreased nicotine self-administration by 75 %, and did not alter food-maintained responding, demonstrating greater specificity relative to bPiDI and bPiDDB, as well as the tertiary amino analog r-bPiDDB. The current work describes the discovery of r-bPiDI, a tertiary amino, α-conotoxin MII-like small molecule that acts as a potent and selective antagonist at α6β2* nAChRs to specifically decrease nicotine self-administration in rats, thus, establishing r-bPiDI as a lead compound for development as a treatment for nicotine addiction. Keywords Nicotine Abuse Dopamine Reinforcement